To overcome resistance and enhance antitumor immunity, we rationally engineered the tumor-activated prodrug H62, which combines a potent DHODH inhibitor (EA6) with a validated STING agonist (MSA) via a protease-cleavable linker. Here, DHODH is linked to neoplasm.